Monoclonal antibody manufacturing in transgenic plants--myths and realities.
The number and types of antibodies expressed in plants has increased steadily since the first reports of this accomplishment in the 1980s, illustrating the versatility of plants as a production system for antibodies. Many recent reviews have detailed the antibody forms that have been derived from plant expression systems. This contribution focuses on the remaining challenges to develop plant-derived therapeutic antibodies into products, and some of the progress that is being made in addressing these challenges.
Hood
Elizabeth E
EE
ProdiGene, Inc., 101 Gateway Blvd, Suite 100, College Station, Texas 77845, USA. eha105@aol.com
Woodard
Susan L
SL
Horn
Michael E
ME
D000911:Antibodies, Monoclonal / Q000096:biosynthesis* / Q000191:economics; D004345:Drug Industry / Q000191:economics / Q000379:methods; D018506:Gene Expression Regulation, Plant; D006019:Glycolysis / Q000235:genetics; D030821:Plants, Genetically Modified / Q000276:immunology / Q000378:metabolism*; D012639:Seeds / Q000235:genetics* / Q000378:metabolism*; D014342:Truth Disclosure; D003313:Zea mays / Q000235:genetics* / Q000378:metabolism*
D000911:Antibodies, Monoclonal